ertugliflozin / metformin hydrochloride
Segluromet is a medicine used to treat adults with type 2 diabetes together with diet and exercise.
Segluromet can be used alone or together with other diabetes medicines when glucose (sugar) levels in the blood are insufficiently controlled by other metformin-based treatments.
It can also be used as a replacement in patients who are already taking ertugliflozin and metformin as separate tablets.
Segluromet contains two active substances, ertugliflozin and metformin.
Segluromet : EPAR - Medicine overview (PDF/147.38 KB)
First published: 05/04/2018
Last updated: 16/02/2022
Segluromet : EPAR - Risk management plan summary (PDF/183.41 KB)
First published: 16/02/2022
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Diabetes Mellitus, Type 2
|Anatomical therapeutic chemical (ATC) code||
Merck Sharp & Dohme B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
25/10/2021 Segluromet - EMEA/H/C/004314 - WS/1953
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Drugs used in diabetes
Combinations of oral blood glucose lowering drugs
Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:
- in patients not adequately controlled on their maximally tolerated dose of metformin alone
- in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes
- in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.